Brain volume loss during the first year and physical and cognitive impairment over 3 years in naive multiple sclerosis patients under fingolimod

被引：0
|
作者：
Rojas, J. [1 ]
Sanchez, F. [1 ]
Patrucco, L. [2 ]
Papolla, A. [2 ]
Miguez, J. [3 ]
Cristiano, E. [1 ]
机构：
[1] Ctr Esclerosis Multiple Buenos Aires CEMBA, Buenos Aires, DF, Argentina
[2] Hosp Italiano Buenos Aires, Buenos Aires, DF, Argentina
[3] Hosp Italiano Buenos Aires, Buenos Aires, DF, Argentina
来源：
MULTIPLE SCLEROSIS JOURNAL | 2020年 / 26卷 / 3_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P0841
引用
收藏
页码：518 / 519
页数：2
相关论文
共 50 条
  • [41] Clinical and MRI Dissociation in Patients with Multiple Sclerosis Show No Difference in Cognitive and Quality of Life Measures and Is Not Explained by Loss of Brain Volume or the Presence of Spinal Cord Lesions
    Kolb, Channa
    Healy, Brian
    Glanz, Bonnie
    Bakshi, Rohit
    Guttmann, Charles
    Weiner, Howard
    Buckle, Guy
    NEUROLOGY, 2011, 76 (09) : A326 - A327
  • [42] Treatment-naive patients with active relapsing-remitting multiple sclerosis at baseline demonstrate slowing of brain volume loss with alemtuzumab: 5-year outcomes from the CARE-MS I extension study
    Schippling, S.
    Rovira, A.
    Giovannoni, G.
    Arnold, D. L.
    Traboulsee, A.
    Margolin, D. H.
    Thangavelu, K.
    Filippi, M.
    EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 : 824 - 825
  • [43] Absence of HDL Decrease after Interferon Beta-1a Initiation Is Associated with Greater Brain Volume Loss and Lesion Burden in Multiple Sclerosis Patiens over 4 Years
    Uher, Tomas
    Horakova, Dana
    Fellows, Kelly
    Vaneckova, Manuela
    Sobisek, Lukas
    Seidh, Zdenek
    Tyblova, Michaela
    Krasensky, Jan
    Havrdova, Eva
    Ramanathan, Murali
    NEUROLOGY, 2016, 86
  • [44] Relationship Between Baseline Cognitive Performance and Brain Volume Outcomes in Patients With Relapsing Multiple Sclerosis in ENLIGHTEN: a Phase 3b Study of Ozanimod
    Zivadinov, R.
    DeLuca, J.
    Riolo, J. V.
    Cheng, C.
    Wray, S.
    Bass, A.
    Fox, E.
    Riser, E.
    Chaudhry, B.
    Reardon, J.
    Silva, D.
    Naismith, R. T.
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 188 - 189
  • [45] Objectively assessed physiological, physical, and cognitive function along with patient-reported outcomes during the first 2 years of Alemtuzumab treatment in multiple sclerosis: a prospective observational study
    Lars G. Hvid
    Egon Stenager
    Ulrik Dalgas
    Journal of Neurology, 2022, 269 : 4895 - 4908
  • [46] Objectively assessed physiological, physical, and cognitive function along with patient-reported outcomes during the first 2 years of Alemtuzumab treatment in multiple sclerosis: a prospective observational study
    Hvid, Lars G.
    Stenager, Egon
    Dalgas, Ulrik
    JOURNAL OF NEUROLOGY, 2022, 269 (09) : 4895 - 4908
  • [47] Alemtuzumab-treated patients with active relapsing-remitting multiple sclerosis demonstrate durable slowing of brain volume loss over 5 years with most not receiving treatment for 4 years-CARE-MS I and II extension study
    Inshasi, Jihad Said
    Al Jumah, Mohammed
    Alroughani, Raed
    Compston, D. Alasdair S.
    Filippi, Massimo
    Giovannoni, Gavin
    Havrdova, Eva
    Yamout, Bassem
    Margolin, David H.
    Thangavelu, Karthinathan
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (06) : NP7 - NP7
  • [48] Cognitive and clinical effects of subcutaneous interferon beta-1a in patients with early relapsing-remitting multiple sclerosis: 2- and 3-year results from the COGIMUS (COGnition Impairment in MUltiple Sclerosis) study
    Patti, F.
    Amato, M. P.
    Tola, M. R.
    Trojano, M.
    Ferrazza, P.
    Picconi, O.
    Bastianello, S.
    JOURNAL OF NEUROLOGY, 2008, 255 : 142 - 143
  • [49] Quality of life, depression and fatigue in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study
    Patti, F.
    Amato, M. P.
    Trojano, M.
    Bastianello, S.
    Tola, M. R.
    Picconi, O.
    Cilia, S.
    Cottone, S.
    Centonze, D.
    Gasperini, C.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 (08) : 991 - 1001
  • [50] Treatment-naive patients who had highly active relapsing-remitting multiple sclerosis at baseline demonstrate persistent suppression of MRI activity and brain atrophy with alemtuzumab over 5 years
    Limmroth, V.
    Vermersch, P.
    Lycke, J.
    Singer, B.
    Krieger, S.
    Margolin, D. H.
    Thangavelu, K.
    Traboulsee, A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 : 314 - 314
12345